fda drug shortages semaglutide injection shortage resolved 2025 GLP-1 No Longer on FDA's List Drug shortages in 2024 reach

Treatment durations can range from a few weeks to several months, depending on the desired results

Important safety considerations include the boxed warning for thyroid C-cell tumors (contraindicated in patients with personal/family history of medullary thyroid carcinoma or MEN2), risk of pancreatitis, gallbladder disease, and acute kidney injury

Its a painstaking process to ensure purity, consistency, and lab reliability, but its all for naught if the peptide isn't stored correctly

Sulphonylureas (e.g., gliclazide): these stimulate insulin release but carry a risk of hypoglycaemia and weight gain, requiring education and monitoring

While brand-name options assure FDA approval, compounded versions may offer cost-effective and accessible alternatives